Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling

Basic Research in Cardiology

Volumn 106, Issue 1, 2011, Pages 147-162

  Ghaboura, Nehmat ^a   Tamareille, Sophie ^a   Ducluzeau, Pierre Henri ^b   Grimaud, Linda ^c   Loufrani, Laurent ^c   Croué, Anne ^d   Tourmen, Yves ^d   Henrion, Daniel ^c   Furber, Alain ^a,d   Prunier, Fabrice ^a,d  

^a UNIVERSITÉ D'ANGERS   (France)

^b Universite d'Angers   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cardioprotection; Diabetes; Erythropoietin; Ischemia; Postconditioning

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ERYTHROPOIETIN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHOTRANSFERASE; PROTEIN KINASE B; REPERFUSION INJURY SALVAGE KINASE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISOLATED HEART; LIPID DIET; NONHUMAN; RAT; RECEPTOR DENSITY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES;

EID: 79151485329     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-010-0130-3     Document Type: Article

References (56)

1. J Amour AK Brzezinska Z Jager C Sullivan D Weihrauch J Du N Vladic Y Shi DC Warltier PF Pratt Jr JR Kersten 2010 Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms Anesthesiology 112 576 585 1:CAS:528:DC%2BC3cXitlWmsb8%3D 10.1097/ALN. 0b013e3181cded1f 20124983
2. GS Bhamra DJ Hausenloy SM Davidson RD Carr M Paiva AM Wynne MM Mocanu DM Yellon 2008 Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening Basic Res Cardiol 103 274 284 1:CAS:528:DC%2BD1cXmtlSgtrY%3D 10.1007/s00395-007-0691-y 18080084
3. AJ Bullard P Govewalla DM Yellon 2005 Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo Basic Res Cardiol 100 397 403 1:CAS:528:DC%2BD2MXhtFemur7N 10.1007/s00395-005-0537-4 15944807
4. L Calvillo R Latini J Kajstura A Leri P Anversa P Ghezzi M Salio A Cerami M Brines 2003 Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci USA 100 4802 4806 1:CAS:528:DC%2BD3sXjt12nsbs%3D 10.1073/pnas.0630444100 12663857
5. A Ceylan-Isik T Hunkar E Asan F Kaymaz N Ari T Soylemezoglu N Renda H Soncul M Bali C Karasu 2007 Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats J Pharm Pharmacol 59 1629 1641 1:CAS:528:DC%2BD1cXjs1I%3D 10.1211/jpp.59.12.0004 18053324
6. R Dikow C Wasserhess K Zimmerer LP Kihm M Schaier V Schwenger S Hardt C Tiefenbacher H Katus M Zeier LM Gross 2009 Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats Basic Res Cardiol 104 571 579 1:CAS:528:DC%2BD1MXpsFelsb0%3D 10.1007/s00395-009-0018-2 19288152
7. UD Dincer KR Bidasee S Guner A Tay AT Ozcelikay VM Altan 2001 The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts Diabetes 50 455 461 1:CAS:528:DC%2BD3MXhtVOgsLg%3D 10.2337/diabetes.50.2. 455 11272160
8. P Ferdinandy R Schulz GF Baxter 2007 Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning Pharmacol Rev 59 418 458 1:CAS:528:DC%2BD1cXhsVCiuro%3D 10.1124/pr.107.06002 18048761
9. M Flamment N Gueguen C Wetterwald G Simard Y Malthiery PH Ducluzeau 2009 Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet Am J Physiol Endocrinol Metab 297 E1162 E1170 1:CAS:528:DC%2BD1MXhsVahtr7J 10.1152/ajpendo.00169.2009
10. ER Gross AK Hsu GJ Gross 2007 Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta Diabetes 56 127 136 1:CAS:528:DC%2BD2sXhtVWlt74%3D 10.2337/db06-0907 17192474
11. C Guillard S Chretien AS Pelus F Porteu O Muller P Mayeux V Duprez 2003 Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i)protein beta gamma-subunit-initiated pathway J Biol Chem 278 11050 11056 1:CAS:528:DC%2BD3sXit1Kgsrg%3D 10.1074/jbc.M208834200 12538595
12. PR Hanlon P Fu GL Wright C Steenbergen MO Arcasoy E Murphy 2005 Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling FASEB J 19 1323 1325 1:CAS:528:DC%2BD2MXntlaqs7w%3D 15946993
13. DJ Hausenloy A Tsang DM Yellon 2005 The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning Trends Cardiovasc Med 15 69 75 1:CAS:528:DC%2BD2MXktVOisLw%3D 10.1016/j.tcm.2005.03.001 15885573
14. DJ Hausenloy DM Yellon 2004 New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc Res 61 448 460 1:CAS:528:DC%2BD2cXhtFWmsL8%3D 10.1016/j.cardiores.2003.09.024 14962476
15. G Heusch 2009 No RISK, no cardioprotection? A critical perspective Cardiovasc Res 84 173 175 1:CAS:528:DC%2BD1MXht1OrtLvK 10.1093/cvr/cvp298 19713282
16. G Heusch K Boengler R Schulz 2008 Cardioprotection: nitric oxide, protein kinases, and mitochondria Circulation 118 1915 1919 10.1161/CIRCULATIONAHA.108. 805242 18981312
17. M Joyeux-Faure E Rossini C Ribuot P Faure 2006 Fructose-fed rat hearts are protected against ischemia-reperfusion injury Exp Biol Med (Maywood) 231 456 462 1:CAS:528:DC%2BD28Xjt1Sjtb0%3D
18. M Juhaszova DB Zorov SH Kim S Pepe Q Fu KW Fishbein BD Ziman S Wang K Ytrehus CL Antos EN Olson SJ Sollott 2004 Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore J Clin Invest 113 1535 1549 1:CAS:528: DC%2BD2cXkvVOqsbk%3D 15173880
19. Z Kaygisiz N Erkasap N Yazihan K Sayar H Ataoglu R Uyar M Ikizler 2006 Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts J Physiol Sci 56 247 251 1:CAS:528:DC%2BD28XhtVOqtL7N 10.2170/physiolsci.RP004806 16839461
20. F Kehl JG Krolikowski B Mraovic PS Pagel DC Warltier JR Kersten 2002 Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction Anesthesiology 96 183 188 1:CAS:528:DC%2BD38XntFehtw%3D%3D 10.1097/00000542-200201000-00032 11753019
21. JR Kersten MW Montgomery T Ghassemi ER Gross WG Toller PS Pagel DC Warltier 2001 Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels Am J Physiol Heart Circ Physiol 280 H1744 H1750 1:CAS:528:DC%2BD3MXjtV2itr0%3D 11247788
22. JR Kersten WG Toller ER Gross PS Pagel DC Warltier 2000 Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality Am J Physiol Heart Circ Physiol 278 H1218 H1224 1:CAS:528:DC%2BD3cXislSlu74%3D 10749717
23. HS Kim JE Cho KC Hwang YH Shim JH Lee YL Kwak 2010 Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival Eur J Pharmacol 628 132 139 1:CAS:528:DC%2BC3cXnvFOmtQ%3D%3D 10.1016/j.ejphar.2009.11.032 19944681
24. SB Kristiansen B Lofgren NB Stottrup D Khatir JE Nielsen-Kudsk TT Nielsen HE Botker A Flyvbjerg 2004 Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes Diabetologia 47 1716 1721 1:STN:280:DC%2BD2crnvFWktA%3D%3D 10.1007/s00125-004-1514-4 15480537
25. J Latifpour JH McNeill 1984 Cardiac autonomic receptors: effect of long-term experimental diabetes J Pharmacol Exp Ther 230 242 249 1:CAS:528:DyaL2cXkvVygsLw%3D 6086879
26. L Laviola G Belsanti AM Davalli R Napoli S Perrini GC Weir R Giorgino F Giorgino 2001 Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart Diabetes 50 2709 2720 1:CAS:528:DC%2BD3MXovVOiu7k%3D 10.2337/diabetes.50.12.2709 11723053
27. SY Lim SM Davidson DM Yellon CC Smith 2009 The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction Basic Res Cardiol 104 781 792 1:CAS:528:DC%2BD1MXht1SktLrK 10.1007/s00395-009-0034-2 19462153
28. E Lipsic P van der Meer RH Henning AJ Suurmeijer KM Boddeus DJ van Veldhuisen WH van Gilst RG Schoemaker 2004 Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion J Cardiovasc Pharmacol 44 473 479 1:CAS:528:DC%2BD2cXnvFamsbY%3D 10.1097/01.fjc.0000140209.04675.c3 15454856
29. Y Liu JD Thornton MV Cohen JM Downey SW Schaffer 1993 Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction Circulation 88 1273 1278 1:STN:280:DyaK3szlvVCitQ%3D%3D 8353889
30. TG Maddaford JC Russell GN Pierce 1997 Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat Am J Physiol 273 H1187 H1192 1:CAS:528:DyaK2sXmtlemtLY%3D 9321805
31. T Miki T Miura H Hotta M Tanno T Yano T Sato Y Terashima A Takada S Ishikawa K Shimamoto 2009 ER stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-GSK-3{beta}-mediated suppression of mitochondrial permeability transition Diabetes 58 2863 2872 1:CAS:528:DC%2BD1MXhsFKlu77M 10.2337/db09-0158 19755525
32. CJ Murray AD Lopez 1997 Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study Lancet 349 1498 1504 1:STN:280:DyaK2szhtVaqsw%3D%3D 10.1016/S0140-6736(96)07492-2 9167458
33. M Nishihara T Miura T Miki M Tanno T Yano K Naitoh K Ohori H Hotta Y Terashima K Shimamoto 2007 Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection J Mol Cell Cardiol 43 564 570 1:CAS:528:DC%2BD2sXht1amsLrK 10.1016/j.yjmcc.2007.08.010 17931653
34. SS Park H Zhao RA Mueller Z Xu 2006 Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta J Mol Cell Cardiol 40 708 716 1:CAS:528: DC%2BD28XjvVGmt74%3D 10.1016/j.yjmcc.2006.01.024 16516918
35. DJ Paulson 1997 The diabetic heart is more sensitive to ischemic injury Cardiovasc Res 34 104 112 1:STN:280:DyaK2szmtV2itA%3D%3D 10.1016/S0008-6363(97) 00018-7 9217879
36. F Prunier O Pfister L Hadri L Liang F Del Monte R Liao RJ Hajjar 2007 Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells Am J Physiol Heart Circ Physiol 292 H522 H529 1:CAS:528:DC%2BD2sXisFGisbw%3D 10.1152/ajpheart.00357.2006 16997893
37. Przyklenk K, Maynard M, Greiner DL, Whittaker P (2010) Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. doi: 10.1089/ars.2010.3343
38. P Rafiee Y Shi J Su KA Pritchard Jr JS Tweddell JE Baker 2005 Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways Basic Res Cardiol 100 187 197 1:CAS:528:DC%2BD2MXkslKls74%3D 10.1007/s00395-004-0508-1 15611843
39. J Raphael Y Gozal N Navot Z Zuo 2010 Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling J Cardiovasc Pharmacol 55 348 357 1:CAS:528:DC%2BC3cXltVWltLc%3D 10.1097/FJC.0b013e3181d26583 20125034
40. T Ravingerova R Stetka K Volkovova D Pancza A Dzurba A Ziegelhoffer J Styk 2000 Acute diabetes modulates response to ischemia in isolated rat heart Mol Cell Biochem 210 143 151 1:CAS:528:DC%2BD3cXmtVWgt78%3D 10.1023/A: 1007129708262 10976767
41. NP Riksen DJ Hausenloy DM Yellon 2008 Erythropoietin: ready for prime-time cardioprotection Trends Pharmacol Sci 29 258 267 1:CAS:528: DC%2BD1cXlslWqu7s%3D 10.1016/j.tips.2008.02.002 18359096
42. S Shanmuganathan DJ Hausenloy MR Duchen DM Yellon 2005 Mitochondrial permeability transition pore as a target for cardioprotection in the human heart Am J Physiol Heart Circ Physiol 289 H237 H242 1:CAS:528:DC%2BD2MXmvVeqtLg%3D 10.1152/ajpheart.01192.2004 15961375
43. A Sharma M Singh 2000 Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart Pharmacol Res 41 635 640 1:CAS:528:DC%2BD3cXjt1ansrk%3D 10.1006/phrs.1999.0631 10816332
44. RJ Sidell MA Cole NJ Draper M Desrois RE Buckingham K Clarke 2002 Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart Diabetes 51 1110 1117 1:CAS:528:DC%2BD38Xis1Oju7Y%3D 10.2337/diabetes.51.4.1110 11916933
45. A Skyschally P van Caster K Boengler P Gres J Musiolik D Schilawa R Schulz G Heusch 2009 Ischemic postconditioning in pigs: no causal role for RISK activation Circ Res 104 15 18 1:CAS:528:DC%2BD1cXhsFSmt7%2FJ 10.1161/CIRCRESAHA.108.186429 19038864
46. S Tamareille N Ghaboura F Treguer D Khachman A Croue D Henrion A Furber F Prunier 2009 Myocardial reperfusion injury management: erythropoietin compared with postconditioning Am J Physiol Heart Circ Physiol 297 H2035 H2043 1:CAS:528:DC%2BD1MXhsFOltLjL 10.1152/ajpheart.00472.2009 19617412
47. K Tanaka F Kehl W Gu JG Krolikowski PS Pagel DC Warltier JR Kersten 2002 Isoflurane-induced preconditioning is attenuated by diabetes Am J Physiol Heart Circ Physiol 282 H2018 H2023 1:CAS:528:DC%2BD38Xks12ns7Y%3D 12003806
48. T Thim JF Bentzon SB Kristiansen U Simonsen HL Andersen K Wassermann E Falk 2006 Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome Clin Sci (Lond) 110 665 671 10.1042/CS20050326
49. H Tong K Imahashi C Steenbergen E Murphy 2002 Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective Circ Res 90 377 379 1:CAS:528:DC%2BD38XitFGhtbc%3D 10.1161/01.RES.0000012567.95445.55 11884365
50. A Tosaki DT Engelman RM Engelman DK Das 1996 The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts Cardiovasc Res 31 526 536 1:STN:280:DyaK283psl2nuw%3D%3D 8689644
51. AF Tramontano R Muniyappa AD Black MC Blendea I Cohen L Deng JR Sowers MV Cutaia N El-Sherif 2003 Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway Biochem Biophys Res Commun 308 990 994 1:CAS:528:DC%2BD3sXmsVGku7c%3D 10.1016/S0006-291X(03)01503-1 12927817
52. A Tsang DJ Hausenloy MM Mocanu RD Carr DM Yellon 2005 Preconditioning the diabetic heart: the importance of Akt phosphorylation Diabetes 54 2360 2364 1:CAS:528:DC%2BD2MXnt1yntro%3D 10.2337/diabetes.54.8.2360 16046302
53. C Wagner I Kloeting RH Strasser C Weinbrenner 2008 Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta J Cardiovasc Pharmacol 52 430 437 1:CAS:528: DC%2BD1cXhsVajur%2FM 10.1097/FJC.0b013e31818c12a7 19033822
54. GL Wright P Hanlon K Amin C Steenbergen E Murphy MO Arcasoy 2004 Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J 18 1031 1033 1:CAS:528:DC%2BD2cXkslWiur8%3D 15059965
55. JJ Wright J Kim J Buchanan S Boudina S Sena K Bakirtzi O Ilkun HA Theobald RC Cooksey KV Kandror ED Abel 2009 Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding Cardiovasc Res 82 351 360 1:CAS:528:DC%2BD1MXksVaktLw%3D 10.1093/cvr/cvp017 19147655
56. DM Yellon DJ Hausenloy 2007 Myocardial reperfusion injury N Engl J Med 357 1121 1135 1:CAS:528:DC%2BD2sXhtVKgtLzF 10.1056/NEJMra071667 17855673